Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Vancouver, Canada and Deerfield, Illinois, USA, February 19, 2007 -- Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) and its co-development partner Astellas Pharma US, Inc. today announced that the...
Read more about Cardiome and Astellas Announce Acceptance of NDA for Review
MELVILLE, N.Y.--(BUSINESS WIRE)--Jan. 29, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European...
Larger vial offers more convenient usage, less waste PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today the availability of their antifungal agent MYCAMINE® (micafungin sodium)...
Read more about Astellas Pharma US, Inc. Announces Availability of MYCAMINE® 100mg Vial
Submission of additional indication supports Astellas' commitment to the Infectious Disease community PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today that, on December 21,...
MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 15, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European Committee...
Rookie Driver J.J. Yeley to Drive VESIcare Car at Bass Pro Shop MBNA 500 Atlanta, GA (October 29, 2006) — It is estimated that 17 million men and women in the United States, especially those age...
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 21, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has begun a Phase III clinical trial of Tarceva® (erlotinib) as a targeted...
MELVILLE, N.Y.--(BUSINESS WIRE)--July 28, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Roche, its international partner for Tarceva® (erlotinib), received a negative...
Two Follow-Up Studies Indicate Better Renal Function for Patients with Chronic Graft Dysfunction Converted to Prograf ® BOSTON, July 25, 2006 – Research presented today at the World Transplant...
ATLANTA, Jun 06, 2006 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided a summary of data from studies involving the company's leading product, Tarceva® (erlotinib),...
ATLANTA, June 5 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals (Nasdaq: OSIP) today presented results from a Phase II study that compared the combinations of...
First Arginine Vasopressin (AVP) Antagonist Approved for the Management of Potentially Life-Threatening Sodium and Water Imbalance PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. today...
MELVILLE, N.Y.--(BUSINESS WIRE)--April 17, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that a New Drug Application has been submitted in Japan covering the use of its flagship...
Acquisition of psoriasis product deepens Astellas’ Commitment to Dermatology franchise Deerfield, IL and Cambridge, MA, April 3, 2006 – Astellas Pharma US, Inc. and Biogen Idec Inc. (NASDAQ:...
Heart indication for Prograf reinforces a 20-year commitment to research and development in transplantation DEERFIELD, IL, APRIL 1, 2006 – The Food and Drug Administration (FDA) has granted...
Vancouver, Canada and Deerfield, Illinois, USA, March 31, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced...
MELVILLE, N.Y., Feb 01, 2006 -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter international sales for its flagship product, Tarceva® (erlotinib). Net international sales...
Recently, new information was added to the US labeling for the class of topical calcineurin inhibitors, or TCIs, which includes Protopic® (tacrolimus) Ointment and pimecrolimus cream. The new...
MELVILLE, N.Y., Jan 11, 2006 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter and year-end net U.S. sales for its flagship product, Tarceva® (erlotinib)....
First arginine vasopressin (AVP) antagonist approved for the management of potentially lifethreatening sodium/water imbalance DEERFIELD, Illinois, December 30 — Astellas Pharma US, Inc. today...
Read more about FDA Approves Astellas' Vaprisol® for the Treatment of Euvolemic Hyponatremia
PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. today announced the appointment of Sef Kurstjens, M.D., Ph.D. as the head of Research and Development activities in the U.S. As Senior Vice...
Read more about Astellas Appoints New U.S. Research & Development Head
Tarceva Now Approved for Advanced Non-Small Cell Lung Cancer and Pancreatic Cancer MELVILLE, N.Y., and SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire- FirstCall/ -- OSI Pharmaceuticals, Inc....
MELVILLE, N.Y. and SOUTH SAN FRANCISCO, Calif.--Nov. 2, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the U.S. Food and Drug Administration...
Vancouver, Canada, October 19, 2005 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced the initiation of an open-label...
MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 12, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today reiterated its confidence in the launch year performance and long-term prospects of its flagship...
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 21, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the...
MELVILLE, NY & SAN FRANCISCO--(BUSINESS WIRE)--Sept. 13, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the Oncologic Drug Advisory Committee...
PALO ALTO, Calif. and DEERFIELD, IL, August 10, 2005 – CV Therapeutics, Inc. (Nasdaq: CVTX) and Astellas Pharma US, Inc. announced today that the first of two pivotal Phase 3 studies of...
Read more about Regadenoson Meets Primary Endpoint in First Phase 3 Trial
MELVILLE, N.Y.--Aug. 8, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Oncologic Drugs Advisory Committee (ODAC) panel will review at its September 13, 2005 meeting the...
MELVILLE, N.Y.--(BUSINESS WIRE)--July 13, 2005--OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) announced today that Health Canada has approved Tarceva® (erlotinib) for the treatment of patients with...
MELVILLE, N.Y.--(BUSINESS WIRE)--June 27, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced today that its ex- U.S. partner for Tarceva® (erlotinib), Roche, received a positive opinion from...
MELVILLE, N.Y., Jun 02, 2005 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced the issuance of U.S. Patent No. 6,900,221 by the United States Patent and Trademark Office....
PRNewswire DEERFIELD, Ill. Astellas US LLC and Astellas Pharma US, Inc. ("Astellas") along with ITEM Development AB ("Item") announced today that they have filed a patent infringement lawsuit in...
Additional Milligram to Milligram Conversion Study Shows Equivalency of Prograf to MR Prograf SEATTLE, May 24, 2005 – Two studies presented today at the 6th American Transplant Congress (ATC)...
One Study of Early Steroid Withdrawal Reduced Cholesterol Levels and Decreased Onset of Post Transplant Diabetes SEATTLE, May 24, 2005 -- Early steroid withdrawal along with the use of tacrolimus...
ORLANDO, Fla., May 17, 2005 -- OSI Pharmaceuticals (Nasdaq: OSIP) First-Line, Monotherapy Non-Small Cell Lung Cancer Data Presented Symptom Response / Quality of Life Analysis from the...
ORLANDO, Fla., May 16, 2005 -- OSI Pharmaceuticals (Nasdaq:OSIP) provided an informational update summarizing highlights from presentations on the analysis of EGFR mutation and gene amplification...
Data Presented at Plenary Session at Annual ASCO Meeting ORLANDO, Fla., May 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals (Nasdaq: OSIP) today...
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 2, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that OSI submitted a...
New Entity Ranks Astellas Among Top 20 Worldwide Pharmaceutical Companies Deerfield, Ill., April 1, 2005—Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. officially...
MELVILLE, N.Y.--(BUSINESS WIRE)--March 22, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Swiss health authority, Swissmedic, has approved Tarceva™ (erlotinib) for the...
PRNewswire DEERFIELD, Ill. Fujisawa Healthcare, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the use of micafungin sodium, the antifungal product for...
PRNewswire DEERFIELD, Ill. and BASEL, Switzerland Fujisawa Healthcare, Inc. and Roche Pharmaceuticals today announced a partnership for the U.S. co-promotion of MYCAMINE™ (micafungin sodium)...
Read more about Fujisawa Healthcare, Inc. and Roche Announce Co-promotion of MYCAMINE™
First Astellas Product Launched in the United States PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent...
Read more about Anti-Fungal Agent MYCAMINE™ Available to Physicians
Tarceva is the Only Epidermal Growth Factor Receptor (EGFR) Therapy to Show an Improvement in Survival in Pancreatic Cancer HOLLYWOOD, Fla.--(BUSINESS WIRE)--Jan. 27, 2005--OSI Pharmaceuticals,...
Follow U.S. news
